Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice

被引：7

作者：

Arai, Takashi ^{[1
]}

Moriyama, Hiroaki ^{[1
]}

Shimizu, Mami ^{[1
]}

Sasaki, Hirotomo ^{[1
]}

Kishi, Minoru ^{[1
]}

Okumachi, Yasuyo ^{[1
]}

Yasuda, Hisafumi ^{[1
]}

Hara, Kenta ^{[1
]}

Yokono, Koichi ^{[1
]}

Nagata, Masao ^{[1
]}

机构：

[1] Kobe Univ, Dept Internal & Geriatr Med, Grad Sch Med, Kobe, Hyogo 657, Japan

来源：

CLINICAL IMMUNOLOGY | 2010年 / 136卷 / 01期

关键词：

Diabetes; Immunotherapy; Insulin; Leader peptide; NOD; Regulatory T cell; NONOBESE DIABETIC MICE; ANTI-CD3; MONOCLONAL-ANTIBODY; INSULIN; ONSET; THERAPY; MOUSE; CYCLOSPORINE; AUTOANTIGEN; PREVENTION; PEPTIDES;

D O I：

10.1016/j.clim.2010.02.016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antigen-specific immunotherapy is expected to be an ideal strategy for treating type 1 diabetes (T1D). We investigated the therapeutic efficacy of a peptide in the leader sequence of preproinsulin, which was selected because of its binding affinity to the MHC I-A(g7) molecule. Preproinsulin-1 L7-24 peptide (L7-24) emulsified in Freund's incomplete adjuvant was administered subcutaneously to NOD mice. Administration of L7-24 increased the proportion of regulatory T cells in the spleen. Splenocytes of NOD mice immunized with this peptide secreted IL-4 and IL-10 in response to L7-24. This peptide also significantly prevented the development of diabetes and cured some newly diabetic NOD mice without recurrence. L7-24 peptide, which has a high affinity for pockets of I-A(g7), induced regulatory T cells and showed therapeutic effects. This peptide may provide a new approach for developing antigen-specific immunotherapy for autoimmune diabetes. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：74 / 82

页数：9

共 33 条

[1] GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes [J].

Agardh, C. -D. ;

Lynch, K. F. ;

Palmer, M. ;

Link, K. ;

Lernmark, A. .

DIABETOLOGIA, 2009, 52 (07) :1363-1368

[2] Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs [J].

Bresson, D ;

Togher, L ;

Rodrigo, E ;

Chen, YL ;

Bluestone, JA ;

Herold, KC ;

von Herrath, M .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1371-1381

[3] Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23) [J].

Daniel, D ;

Wegmann, DR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :956-960

[4]

DIABETES PT, 2002, NEW ENGL J MED, V346, P1685

[5]

DUPRE J, 1988, DIABETES CARE, V11, P37

[6]

EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360

[7] T cell response to preproinsulin I and II in the nonobese diabetic mouse [J].

Halbout, P ;

Briand, JP ;

Bécourt, C ;

Muller, S ;

Boitard, C .

JOURNAL OF IMMUNOLOGY, 2002, 169 (05) :2436-2443

[8] A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes [J].

Herold, KC ;

Gitelman, SE ;

Masharani, U ;

Hagopian, W ;

Bisikirska, B ;

Donaldson, D ;

Rother, K ;

Diamond, B ;

Harlan, DM ;

Bluestone, JA .

DIABETES, 2005, 54 (06) :1763-1769

[9] Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus [J].

Herold, KC ;

Hagopian, W ;

Auger, JA ;

Poumian-Ruiz, E ;

Taylor, L ;

Donaldson, D ;

Gitelman, SE ;

Harlan, DM ;

Xu, DL ;

Zivin, RA ;

Bluestone, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (22) :1692-1698

[10] Low-affinity major histocompatibility complex-binding peptides in type 1 diabetes [J].

James, Eddie A. ;

Kwok, William W. .

DIABETES, 2008, 57 (07) :1788-1789

← 1 2 3 4 →